Quest Partners LLC Has $95,000 Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Quest Partners LLC boosted its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 907.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,237 shares of the medical research company’s stock after acquiring an additional 2,015 shares during the quarter. Quest Partners LLC’s holdings in Exact Sciences were worth $95,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Benjamin F. Edwards & Company Inc. boosted its holdings in Exact Sciences by 65.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock worth $31,000 after acquiring an additional 179 shares during the last quarter. Able Wealth Management LLC purchased a new stake in Exact Sciences in the 4th quarter valued at about $45,000. EverSource Wealth Advisors LLC increased its stake in Exact Sciences by 92.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock valued at $49,000 after buying an additional 340 shares during the last quarter. Fortitude Family Office LLC bought a new position in shares of Exact Sciences during the 1st quarter worth approximately $55,000. Finally, GAMMA Investing LLC lifted its position in shares of Exact Sciences by 48.4% during the 2nd quarter. GAMMA Investing LLC now owns 1,362 shares of the medical research company’s stock worth $58,000 after buying an additional 444 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Stock Down 2.1 %

EXAS opened at $67.99 on Wednesday. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The company has a market cap of $12.55 billion, a PE ratio of -51.51 and a beta of 1.26. The company has a current ratio of 2.17, a quick ratio of 1.98 and a debt-to-equity ratio of 0.73. The company has a 50 day moving average of $55.37 and a 200 day moving average of $55.52.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. The firm had revenue of $699.26 million during the quarter, compared to analyst estimates of $690.02 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period last year, the company earned ($0.45) earnings per share. On average, sell-side analysts expect that Exact Sciences Co. will post -0.87 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Benchmark dropped their price target on Exact Sciences from $91.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Stifel Nicolaus decreased their target price on Exact Sciences from $100.00 to $82.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. BTIG Research cut their price target on shares of Exact Sciences from $80.00 to $70.00 and set a “buy” rating on the stock in a report on Wednesday, June 26th. Scotiabank assumed coverage on shares of Exact Sciences in a research report on Thursday, June 27th. They set a “sector outperform” rating and a $70.00 price target for the company. Finally, Piper Sandler raised their price objective on shares of Exact Sciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, September 12th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $78.14.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.